Compare Boston Beer Company Inc (SAM) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Stryker Corporation — how do they compare? Boston Beer Company Inc trades at $170.75 (market cap $1.88B), while Stryker Corporation trades at $319.04 (market cap $122.35B). The key difference: Stryker Corporation is far larger — about 65.1× Boston Beer Company Inc's market cap, and Stryker Corporation pays a 1% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| SAM | SYK | |
|---|---|---|
Market Cap | $1.88B | $122.35B |
Sector | Consumer Staples | Technology |
52-Week High | $260.05 | $403.53 |
52-Week Low | $161.08 | $282.58 |
Enterprise Value | $1.75B | $134.10B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $170.98, down 4.37% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, though 2026 projections show potential challenges with expected revenue decline and negative margins. Recent earnings show a mix of beats and misses, with Q2 2026 results pending.
The stock presents a cautious opportunity with analyst consensus target of $204.33 suggesting 19% upside, but faces headwinds from declining volumes, competitive pressure in hard seltzer market, and negative FY26 EPS growth projections. Institutional sentiment leans neutral with 74% hold ratings, reflecting balanced risk-reward amid evolving consumer beverage preferences.
Stryker (SYK) trades at $319.14, down 0.23% with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust margins. Recent news highlights Mako RPS launch expansion in robotic surgery, while Q1 2026 earnings missed expectations due to a temporary cyber disruption, though full-year guidance remains unchanged.
Outlook remains positive with 74% analyst buy ratings and a $388.44 consensus price target implying 22% upside. Key risks include competitive pressures and execution challenges from recent cybersecurity issues. The stock presents a growth opportunity in med-tech innovation, trading below historical valuation multiples with healthy cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
